UniCredit Taps Adviser for BPM Bid Branch Sales Amid Deal Doubts
UniCredit SpA has tapped an investment bank to manage the possible sale of branches it needs to carry out if it buys Banco BPM SpA, according to people familiar with the matter.
The Italian lender has asked Kitra Advisory to help it offload branches across Italy in a move that would address demands from the European Union antitrust watchdog if the takeover goes ahead, the people said. The potential disposal of branches is part of a project dubbed Stardust, they said asking to not be named discussing private information.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
CHMP recommends third indication for darolutamide for patients with advanced prostate cancer
ORION CORPORATION PRESS RELEASE 20 JUNE 2025 at 13.30 EEST CHMP recommends third indication for darolutamide for patients with advanced prostate cancer CHMP adopts positive opinion for the marketing authorisation of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the European Union. Positive opinion is based on results from the pivotal Phase III ARANOTE trial. Pending approval, this broadened indication would give doctors the option to use darolutamide plus ADT, with or without chemotherapy (docetaxel), offering greater flexibility to tailor treatment plans to meet mHSPC patients' needs. Orion's collaboration partner Bayer announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended darolutamide, an oral androgen receptor inhibitor (ARi), plus androgen deprivation therapy (ADT) for marketing authorisation in the European Union (EU) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). The CHMP recommendation is based on positive results from the pivotal Phase III ARANOTE trial which showed that darolutamide plus ADT significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT (HR 0.54; 95% CI 0.41–0.71; P<0.0001) in patients with mHSPC. A final decision on marketing authorisation from the European Commission is anticipated in the coming months. The U.S. Food and Drug Administration (FDA) recently approved darolutamide in combination with ADT for mHSPC in June 2025, making it the first and only in the US and FDA-approved ARi for the treatment of patients with mHSPC, in combination with ADT, with or without chemotherapy. Darolutamide, under the brand name Nubeqa®, is approved in over 85 countries for use with ADT and docetaxel in mHSPC, and with ADT alone in non-metastatic castration-resistant prostate cancer (nmCRPC) in patients who are at high risk of developing metastatic disease. Darolutamide is developed jointly by Orion and Bayer. Prostate cancer is the second most common cancer and the fifth most common cause of cancer death in men worldwide. In 2022, an estimated 1.5 million men were diagnosed with prostate cancer, and about 397,000 died from the disease worldwide.1 In Europe, there were almost 474,000 estimated new cases of prostate cancer in 2022 with approximately 115,000 deaths. 2 Prostate cancer diagnoses are projected to increase to 2.9 million by 2040.3 About the ARANOTE trial The ARANOTE trial is a randomized, double-blind, placebo-controlled Phase III study designed to assess the efficacy and safety of darolutamide plus ADT in patients with mHSPC. 669 patients were randomized 2:1 to receive 600mg of darolutamide twice daily or matching placebo in addition to ADT. The primary endpoint of this study is rPFS, measured as time from randomization to date of first documented radiological progressive disease or death due to any cause, whichever occurs first. Secondary endpoints include overall survival (time to death from any cause), time to first castration resistant event, time to initiation of subsequent anti-cancer therapy, time to prostate-specific antigen (PSA) progression, PSA undetectable rates, time to pain progression, and safety assessments. Results from the Phase III ARANOTE trial presented at ESMO 2024 and published in The Journal of Clinical Oncology showed that darolutamide plus ADT significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT (HR 0.54; 95% CI 0.41–0.71; P<0.0001), in patients with mHSPC. Consistent benefits in radiological progression-free survival (rPFS) were observed across prespecified subgroups, including patients with high-volume (HR 0.60, 95% CI: 0.44-0.80) and low-volume (HR 0.30, 95% CI: 0.15-0.60) mHSPC. The incidence of adverse events in the treatment group with darolutamide plus ADT in the ARANOTE study was comparable to placebo plus ADT. Darolutamide plus ADT was generally well tolerated and showed lower discontinuation rates due to adverse events compared to placebo plus ADT. About darolutamide Darolutamide is an oral ARi with a unique chemical structure that binds with high affinity to the androgen receptor and exhibits a strong antagonistic effect against the androgen receptor inhibiting the receptor function and the growth of prostate cancer cells. Additionally, preclinical models and neuroimaging data in healthy humans, support darolutamide's low potential for blood-brain barrier penetration. Darolutamide (plus ADT or plus ADT and docetaxel) demonstrated a side effect profile, in both mHSPC registrational studies where the incidences of adverse events were roughly similar to the respective comparator arm. Darolutamide is a treatment option for doctors and patients, considering its tolerability and low risk of drug interaction. A robust clinical development program is underway investigating darolutamide across various stages of prostate cancer. The program includes the Phase III ARASTEP trial evaluating darolutamide plus ADT compared to ADT alone in hormone-sensitive high-risk biochemical recurrence (BCR) prostate cancer, who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET/CT at baseline. Furthermore, darolutamide is also being investigated by Bayer in the collaborative Phase III DASL-HiCaP (ANZUP1801) trial led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). The study evaluates darolutamide as a treatment for localized prostate cancer in combination with radiotherapy. About metastatic hormone-sensitive prostate cancer At the time of diagnosis, most men have localized prostate cancer, meaning their cancer is confined to the prostate gland and can be treated with curative surgery or radiotherapy. mHSPC is a stage in the disease where the cancer has spread outside of the prostate to other parts of the body. Up to 10% of men will present with mHSPC when first diagnosed.4,5,6 For patients with mHSPC, ADT is the cornerstone of treatment, in combination with chemotherapy docetaxel and/or an androgen receptor inhibitor (ARi). Despite treatment, most men with mHSPC will eventually progress to castration-resistant prostate cancer (CRPC), a condition with limited survival. References Bray F et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Accessed: June 2025. Ferlay J et al. 2024. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available at: Accessed June 2025.. James ND et al. Lancet 2024; 403: 1683–722. Piombino C et al. Cancers (Basel). 2023 Oct 11;15(20):4945. Helgstrand JT et al. Cancer. 2018;124(14):2931-2938. Buzzoni C et al. Eur. Urol. 2015;68:885–890. Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Multi-year Antitrust Investigation Into Alphabet Inc. (GOOG) Concludes
Alphabet Inc. (NASDAQ:GOOG) remains one of the 10 best marketing stocks to buy right now. On Friday, June 13, 2025, Mexico's antitrust watchdog, Cofeco, closed the multi-year antitrust investigation case against Alphabet Inc. (NASDAQ:GOOG). The case began with Cofeco's claim that Google forces advertisers to operate through its services across both search and third-party sites. If the claim had been true, it would have meant that Google gained an unfair advantage over its competitors in the digital advertising sector. The unfair advantage was claimed to stem from the design of Google's platform for buying online advertising. everything possible/ This relieves Google of paying up to 8% of its annual revenue from Mexico as a fine. The scale of this potential antitrust fine can be understood from Google's revenue from Latin America for 2024, which totals over $20 billion. Alphabet Inc. (NASDAQ:GOOG) is one of the best advertising agency stocks to buy right now. In response to this update, a Google spokesperson stated: 'We appreciate COFECE's decision recognizing that our products give advertisers the freedom and control to use our tools in the ways that best suit their needs.' While we acknowledge the potential of GOOG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Marketing Stocks to Buy Right Now and 12 Best Gold Stocks to Invest In According to Billionaires. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
I'm an Economist: 4 Questions To Ask About Tariffs (and 2 Not To Worry About)
President Trump's tariffs has been dominating headlines for months now, prompting concerns about how they may affect everything from grocery bills to investment accounts. While it's tempting to react to every trade policy shift, not all impacts are immediate or relevant to everyday consumers. Trending Now: Try This: Here's a quick breakdown on Trump's tariffs, why they have been implemented, and what everyone knows so far: Tariffs are taxes charged on imported goods. For example, a 10% tariff means a $10 product would have a $1 tax on top, which would make your total $11. President Trump has doubled U.S. tariffs on steel and aluminum imports to 50%. There is a 25% tax on imports from both Canada and Mexico and a 10% levy on Canadian energy. Though there has been a lot of back and forth as to the amount, the current tariff on goods from China is 20%. The White House also implemented a 20% tariff on most European Union goods, but halved it to 10% until July 8, 2025, to allow time for trade talks. Trump is mandating that most countries have a 10% 'baseline' tariff on all goods sent to the U.S. GOBankingRates spoke with Jared Ashworth, Ph.D., assistant professor of economics at Pepperdine Graziadio Business School, to determine the four questions you should be asking about tariffs — and the two things you shouldn't worry about. Most consumers don't need to follow every twist in trade policy. However, they do need to understand how tariffs might affect their wallets, savings and investments. Here are four practical financial questions worth asking right now. Uncertainty is the biggest concern about the tariffs. 'In recent months, there have been significant swings in what the actual tariffs will be,' Ashworth said. 'Many of these tariffs could also be rolled back if, for example, a target country changes its trade policy.' This has caused a lot of uncertainty. 'As a result, financial markets have become much more uncertain. Standard advice about risk and uncertainty, like considering your risk aversion or how close you are to retirement, matters even more in this context,' Ashworth said. Many retailers have already or will likely adjust their prices quickly in anticipation of the tariffs. According to Wired, the price of refrigerator staples like apple juice is already increasing, as most apple juice that Americans drink comes from China. Apple juice is just one of the many goods American consumers count on that will likely become more expensive due to the tariffs. 'The goal of tariffs is to allow domestic firms to charge higher prices and compete with the raised prices of international firms,' Ashworth said. Consumers are making big purchases in anticipation of the tariffs. For example, sales of cars and motor vehicles parts were up by 8.8% from last year, according to U.S. Census Bureau data. 'Most people won't be able to gain by making major changes based on broad news,' Ashworth said. 'For example, with cars, even though the vehicles currently on lots weren't directly affected by tariffs, the rush to buy before the tariffs take full effect has driven up prices.' According to USA Today, the manufacturing, construction, transportation, warehousing, retail and supply chain sectors are most likely to be affected by tariffs and are paring back on hiring. Ashworth said individuals should consider shifting investments to companies less affected by tariffs, even though the market expectations are already reflected in stock prices. Healthcare and financial services are among the sectors that are still poised to grow or remain stable, per USA Today. Tariffs can feel like a threat to every part of one's financial life, but not all impacts are immediate or personal. Here's what to set aside for now. The uncertainty about the impact of the tariffs also means that it's hard to know what will happen next or how long the effects will last. 'While the U.S. is part of a globally connected economy, imports and exports still make up a relatively small percentage of the GDP (Gross Domestic Product),' Ashworth said. 'The idea of a full-out trade war often depends on how it's framed, which is part of the problem.' For example, tariffs are viewed as either a measure that protects domestic industries or a policy that punishes countries engaging in unfair trade. 'But those goals can be contradictory,' Ashworth said. 'If tariffs are a punishment, then the once the country reforms its trade practices, we're expected to drop the tariffs, potentially ending the protection for domestic industries.' It's easy to feel powerless when trade policy shifts overnight. But for most consumers, the best response isn't control; it's adaptability. 'While tariffs can affect exchange rates and relative interest rates, most of those impacts aren't something everyday people can or should try to take advantage of,' Ashworth said. 'Unless you have direct influence over national policy, there's little you can do to change it. Instead, focus on staying flexible in this period of heightened uncertainty.' While there isn't much that can be done when it comes to government policy, consumers can take other actions to protect themselves and their finances. 'As with any pressure that raises prices, find ways to reduce consumption and spend less. While tariffs might contribute to a recession, individuals should still prioritize cutting back on spending and increasing savings,' Ashworth said. Caitlyn Moorhead contributed to the reporting for this article. More From GOBankingRates Clever Ways To Save Money That Actually Work in 2025 This article originally appeared on I'm an Economist: 4 Questions To Ask About Tariffs (and 2 Not To Worry About) Sign in to access your portfolio
